Enliven Therapeutics (ELVN) News Today → POTUS in ‘25 Not Biden/Trump, But (From The Freeport Society) (Ad) Free ELVN Stock Alerts $23.04 -0.77 (-3.23%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 2:18 AM | americanbankingnews.comEquities Analysts Issue Forecasts for Enliven Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ELVN)May 17 at 1:31 PM | insidertrades.comAnish Patel Sells 1,107 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockMay 17 at 7:50 AM | marketbeat.comLifesci Capital Weighs in on Enliven Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ELVN)Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - Investment analysts at Lifesci Capital issued their Q2 2024 earnings per share (EPS) estimates for shares of Enliven Therapeutics in a note issued to investors on Wednesday, May 15th. Lifesci Capital analyst S. Slutsky expects that the compMay 16 at 9:50 PM | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $27,675.00 in StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 1,107 shares of the firm's stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $25.00, for a total value of $27,675.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.May 15 at 7:47 AM | finanznachrichten.deEnliven Therapeutics, Inc.: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business UpdateMay 15 at 12:07 AM | investorplace.comELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q1 2024May 14, 2024 | globenewswire.comEnliven Therapeutics Reports First Quarter Financial Results and Provides a Business UpdateMay 13, 2024 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Shares Gap Up to $23.43Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up to $23.43May 9, 2024 | insidertrades.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells 4,875 Shares of StockMay 8, 2024 | insidertrades.comBenjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockMay 7, 2024 | marketbeat.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 1,000 Shares of StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 1,000 shares of the stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $22.50, for a total value of $22,500.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.May 7, 2024 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Trading 6.2% Higher Enliven Therapeutics (NASDAQ:ELVN) Shares Up 6.2%May 3, 2024 | insidertrades.comBenjamin Hohl Sells 3,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockMay 2, 2024 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $55,152.50 in StockMay 1, 2024 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 3,250 SharesEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $16.97, for a total transaction of $55,152.50. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.April 30, 2024 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Sees Unusually-High Trading VolumeEnliven Therapeutics (NASDAQ:ELVN) Sees Large Volume IncreaseApril 30, 2024 | marketbeat.comShort Interest in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Expands By 9.7%Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) was the target of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 4,640,000 shares, an increase of 9.7% from the March 31st total of 4,230,000 shares. Based on an average daily volume of 247,800 shares, the short-interest ratio is presently 18.7 days. Approximately 18.3% of the company's stock are short sold.April 30, 2024 | insidertrades.comSamuel Kintz Sells 12,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockApril 29, 2024 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $202,680.00 in StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 12,000 shares of the stock in a transaction that occurred on Thursday, April 25th. The stock was sold at an average price of $16.89, for a total transaction of $202,680.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.April 29, 2024 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Stock Price Up 7.5%Enliven Therapeutics (NASDAQ:ELVN) Trading Up 7.5%April 28, 2024 | nasdaq.comCommit To Purchase Enliven Therapeutics At $10, Earn 11.2% Annualized Using OptionsApril 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Apellis Pharmaceuticals Amid Positive Outlook and Growth PotentialApril 26, 2024 | markets.businessinsider.comBuy Rating Affirmed: Enliven Therapeutics’ ELVN-001 Shows Market Potential and Efficacy in Resistant PatientsApril 19, 2024 | finance.yahoo.comMasterCraft Boat, SentinelOne, and More Stocks See Action From Activist InvestorsApril 19, 2024 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Sees Large Volume IncreaseEnliven Therapeutics (NASDAQ:ELVN) Sees Strong Trading VolumeApril 18, 2024 | msn.comEnliven Therapeutics files to sell 6.43M shares for holdersApril 18, 2024 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Trading 4.7% Higher Enliven Therapeutics (NASDAQ:ELVN) Shares Up 4.7%April 17, 2024 | msn.comEnliven Therapeutics (ELVN) Price Target Increased by 10.75% to 35.02April 16, 2024 | investing.comEnliven Therapeutics CMO sells $501k in company stockApril 16, 2024 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman Sells 1,270 SharesApril 16, 2024 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells $25,387.30 in StockApril 15, 2024 | marketbeat.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 1,270 Shares of StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Richard A. Heyman sold 1,270 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $19.99, for a total value of $25,387.30. Following the completion of the transaction, the director now owns 137,155 shares of the company's stock, valued at $2,741,728.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.April 15, 2024 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Shares Down 3.6% After Insider SellingEnliven Therapeutics (NASDAQ:ELVN) Stock Price Down 3.6% Following Insider SellingApril 13, 2024 | insidertrades.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 53,400 Shares of StockApril 12, 2024 | investing.comEnliven reports promising Phase 1 data for leukemia drugApril 11, 2024 | markets.businessinsider.comStrong Buy Rating for Enliven Therapeutics’ ELVN-001 Following Outstanding Phase 1 Results and Market PotentialApril 11, 2024 | finance.yahoo.comEnliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead ProgramApril 11, 2024 | msn.comEnliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On ThursdayApril 11, 2024 | marketwatch.comEnliven Therapeutics Shares Hit 52-Week High After Positive Proof of Concept Data for Blood Cancer DrugApril 11, 2024 | proactiveinvestors.comEnliven Therapeutics shares rise on promising preliminary data for blood cancer drugApril 11, 2024 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Sets New 52-Week High at $26.00Enliven Therapeutics (NASDAQ:ELVN) Hits New 1-Year High at $26.00April 11, 2024 | globenewswire.comEnliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid LeukemiaApril 11, 2024 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 4,875 SharesApril 10, 2024 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Stock Price Up 3.5%Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 3.5%April 9, 2024 | markets.businessinsider.comEnliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst SaysApril 9, 2024 | globenewswire.comEnliven Therapeutics Appoints Dr. Lori Kunkel to Board of DirectorsApril 9, 2024 | finance.yahoo.comOwning 36% shares,institutional owners seem interested in Enliven Therapeutics, Inc. (NASDAQ:ELVN),April 9, 2024 | marketbeat.comMizuho Begins Coverage on Enliven Therapeutics (NASDAQ:ELVN)Mizuho assumed coverage on shares of Enliven Therapeutics in a report on Tuesday. They set a "buy" rating and a $34.00 target price on the stock.April 9, 2024 | insidertrades.comRahul D. Ballal Sells 3,485 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockApril 8, 2024 | marketbeat.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 3,485 Shares of StockEnliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Rahul D. Ballal sold 3,485 shares of the company's stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $19.15, for a total transaction of $66,737.75. Following the sale, the director now owns 22,341 shares of the company's stock, valued at approximately $427,830.15. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address A once-in-a-century investment opportunity (Ad)It's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more potential than the AI stocks most investors are focused on in the days ahead. To get its name and ticker symbol for free - just click here. ELVN Media Mentions By Week ELVN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELVN News Sentiment▼0.750.52▲Average Medical News Sentiment ELVN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELVN Articles This Week▼112▲ELVN Articles Average Week Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AbCellera Biologics News Today Prothena News Today Verona Pharma News Today Collegium Pharmaceutical News Today Mirum Pharmaceuticals News Today Ironwood Pharmaceuticals News Today Belite Bio News Today MannKind News Today Innoviva News Today Cassava Sciences News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELVN) was last updated on 5/18/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceThe Presidential candidate you should REALLY be worried aboutStansberry ResearchProtect Your Bank Account Before It’s Too LateWeiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressWhat’s Really Next for America…Porter & CompanyHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
